Taking on moderate to severe Alzheimer's disease with combination therapy
Combination therapy with NAMENDA (memantine HCl) and ARICEPT* (donepezil HCl 5-10 mg)
may provide benefits in thinking, daily functioning, and behavior in people with
moderate to severe Alzheimer's disease.
There is no evidence that NAMENDA or donepezil prevents or slows the underlying disease process in patients with Alzheimer’s disease.
Combination therapy has been shown to be effective at slowing the progression of moderate to severe Alzheimer's disease symptoms
A study published in the Journal of the American Medical Association showed
that combination therapy with NAMENDA and ARICEPT* (donepezil HCl 5-10 mg) was more effective at slowing the
progression of symptoms than remaining on ARICEPT alone.
Use this guide to talk to your doctor about how adding NAMENDA can help your loved one.
There is no evidence that NAMENDA or donepezil prevents or slows the
underlying disease process in patients with Alzheimer’s disease.
Combination therapy with NAMENDA has a low incidence of side effects
A clinical study has shown that combination therapy with NAMENDA and ARICEPT* (donepezil HCl 5-10 mg) has
a low incidence of side effects. Also, NAMENDA has a low potential of interacting with
other medicines that your loved one may be taking.
Ask your doctor about a treatment that may benefit your loved one's moderate to severe
Alzheimer's symptoms and has a low incidence of side effects.
There is no evidence that NAMENDA or donepezil prevents or slows the
underlying disease process in patients with Alzheimer’s disease.